- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04397497
Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) (COMBAT-19)
A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)
Study Overview
Status
Intervention / Treatment
Detailed Description
To evaluate the efficacy and safety of mavrilimumab versus placebo in addition to best standard of care (SoC) in the treatment of COVID-19 pneumonia.
As of May 13, 2020, COVID-19 has been confirmed in more than 4.2 million people worldwide. Mortality rate has been reported to be approximately 3.7%, which is nearly 4 times higher than that of influenza: there is an urgent need for effective treatment.
Accumulating evidence suggests that patients with severe acute COVID-19 pneumonia have a cytokine storm syndrome, or unbalanced hyper-inflammatory response resulting in markedly elevated cytokine and chemokine production.
GM-CSF is a cytokine with dual roles as a critical pulmonary hormone and proinflammatory properties that can exaggerate tissue inflammation. Recent preliminary uncontrolled clinical observations on 13 non-mechanically-ventilated patients in the promoter institution suggest that GM-CSF pathway blockade with mavrilimumab is an effective and well-tolerated treatment for COVID-19 pneumonia.
We will perform a prospective, phase II, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of mavrilimumab in hospitalized patients with acute respiratory failure requiring oxygen supplementation in COVID- 19 pneumonia and a hyper-inflammatory status. The study will randomize non-mechanically-ventilated adult patients to mavrilimumab or placebo, in addition to standard of care per local practice, which may include but not limited to anti-viral treatment, hydroxychloroquine, low-dose corticosteroids (≤ 10 mg of prednisone or equivalent) and/or supportive care. The total trial duration will be 12 weeks after single mavrilimumab or placebo infusion. Safety will be closely monitored by a dedicated external data safety monitoring board (DSMB) at regular intervals during the study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lorenzo Dagna, MD
- Phone Number: +390226434683
- Email: dagna.lorenzo@unisr.it
Study Contact Backup
- Name: Giacomo De Luca, MD
- Phone Number: +390226434683
- Email: deluca.giacomo@hsr.it
Study Locations
-
-
-
Milano, Italy, 20132
- IRCCS Ospedale San Raffaele
-
Contact:
- Giacomo De Luca, MD
-
Milano, Italy, 20161
- IRCCS Istituto Ortopedico Galeazzi
-
-
MI
-
San Donato, MI, Italy, 20097
- IRCCS Policlinico San Donato
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults (≥ 18 years of age)
- Signed informed consent by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representative or according to local guidelines
- Patients clinically diagnosed with SARS-CoV-2 virus by PCR or by other approved diagnostic methodology
- Hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray or CT scan with pulmonary infiltrates
- Patient requiring oxygen supplementation (i.e. with a SpO2 ≤ 92% while breathing room air) and having a PAO2/FIO2 ratio ≤ 300 mmHg
Lactate dehydrogenase (LDH) > normal range and at least one of the following:
- fever > 38.0 °C;
- increased levels of C-reactive Protein (CRP) ≥ 10x UNL mg/L (≥ 60 mg/l);
- increased levels of ferritin ≥ 2.5x UNL ( ≥ 1000 μg/L)
Exclusion Criteria:
- Onset of COVID-19 pneumonia symptoms (i.e. dyspnea/respiratory insufficiency) >14 days
- On mechanical ventilation at the time of randomization
- A PaO2/FiO2 < 100 mmHg
- Uncontrolled systemic infection (other than COVID-19)
- Hypersensitivity to the active substance or to any of the excipients of the experimental drug
- Total neutrophil count < 1500/mm3
- Severe hepatic cirrhosis
- History of chronic HBV or HCV infection
- Known or active tuberculosis (TB) or a history of incompletely treated TB; suspected or known extrapulmonary tuberculosis
- Moderate/severe heart failure (NYHA Class 3 or 4)
Any prior (within the defined periods below) or concurrent use of immunosuppressive therapies including but not limited to the following:
- Anti-IL-6, anti-IL-6R antagonists or Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period;
- Cell-depleting agents (e.g., anti CD20) without evidence of recovery of B cells to baseline level;
- Anakinra within 1 week of baseline; canakinumab within 8 weeks of baseline; abatacept within 8 weeks of baseline.
- Tumor necrosis factor (TNF) inhibitors within 2-8 weeks (etanercept within 2 weeks, infliximab, certolizumab, golimumab, or adalimumab within 8 weeks), or after at least 5 half-lives have elapsed, whichever is longer;
- Alkylating agents including cyclophosphamide (CYC) within 6 months of baseline;
- Cyclosporine (CsA), azathioprine (AZA) or mycophenolate mofetil (MMF) or leflunomide or methotrexate within 4 weeks of baseline.
- Pregnancy or lactation (Note: Women of childbearing age should use effective contraception/abstinence after treatment with mavrilimumab and for 3 months after the dosing)
- Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
- In the opinion of the investigator, progression to death is imminent and highly likely within the next 24 hours, irrespective of the provision of treatments
- Current participation in any other interventional investigational trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mavrilimumab
Single dose of IV Mavrilimumab
|
human monoclonal antibody targeting GM-CSF receptor-alpha
Other Names:
|
Placebo Comparator: Placebo
Single dose of matching IV placebo
|
matching volume of diluent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in the dependency on oxygen supplementation
Time Frame: within day 14 of treatment
|
Time to the absence of need for oxygen supplementation (time to first period of 24 hrs with a SpO2 of 94%) within day 14 of treatment, stated as Kaplan- Mayer estimates of the proportion of patients on room air at day 14 and median time to room air attainment in each arm
|
within day 14 of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of responders (using the WHO 7-point ordinal scale)
Time Frame: Day 7, 14, and 28
|
Response is defined as a 7-point ordinal scale of 3 or less, i.e. no supplemental oxygen
|
Day 7, 14, and 28
|
Time to response (using the WHO 7-point ordinal scale)
Time Frame: Within day 28 of intervention
|
Time from date of randomization to the date with a 7-point ordinal scale of 3 or less, i.e. no supplemental oxygen
|
Within day 28 of intervention
|
Proportion of improving patients (using the WHO 7-point ordinal scale)
Time Frame: At day 7, 14, and 28
|
Proportion of patients with at least two-point improvement in clinical status
|
At day 7, 14, and 28
|
Time to resolution of fever
Time Frame: Within day 28 of intervention
|
Time to resolution of fever (for at least 48 hours) in absence of antipyretics, or discharge, whichever is sooner
|
Within day 28 of intervention
|
Reduction in case fatality
Time Frame: Within day 28 of intervention
|
COVID-19-related death
|
Within day 28 of intervention
|
Proportion of patient requiring mechanical ventilation/deaths
Time Frame: Within day 14 of intervention
|
Proportion of hospitalized patients who died or required mechanical ventilation (WHO Categories 6 or 7)
|
Within day 14 of intervention
|
Change in biochemical markers
Time Frame: Within day 28 of intervention or discharge -whatever comes first
|
Change of the following serological markers over follow-up (C-reactive protein; Ferritin; D-Dimer)
|
Within day 28 of intervention or discharge -whatever comes first
|
Median changes in the National Early Warning Score 2 (NEWS2)
Time Frame: At day 7, 14, and 28
|
Median changes of NEWS2 score from baseline
|
At day 7, 14, and 28
|
Time to clinical improvement as evaluated with the National Early Warning Score 2 (NEWS2)
Time Frame: Within day 28 of intervention or discharge -whatever comes first
|
Time to clinical improvement (as defined as a NEWS2 score of 2 or less maintained for at least 24 hours or discharge, whichever comes first)
|
Within day 28 of intervention or discharge -whatever comes first
|
Variations in radiological findings
Time Frame: Within day 28 of intervention or discharge -whatever comes first
|
Variations from baseline to subsequent timepoints (when available) in terms of percentage of lung involvement, modifications in the normal parenchyma, ground glass opacities (GGO), crazy paving pattern,parenchymal consolidations, and evolution towards fibrosis.
|
Within day 28 of intervention or discharge -whatever comes first
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: By day 84
|
Number of patients with treatment- related side effects (as assessed by Common Terminology Criteria for Adverse Event (CTCAE) v.5.0), serious adverse events, adverse events of special interest, clinically significant changes in laboratory measurements and vital signs
|
By day 84
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy of mavrilimumab compared to the control arm by clinical severity
Time Frame: Within day 28 of intervention
|
To evaluate the primary and secondary endpoints in different subgroups of patients:
|
Within day 28 of intervention
|
Changes in serum IL-6 (exploratory biomarker)
Time Frame: By day 84
|
Median changes in serum IL-6
|
By day 84
|
Changes in serum IL-1RA (exploratory biomarker)
Time Frame: By day 84
|
Median changes in serum IL-1 receptor antagonist
|
By day 84
|
Changes in serum TNF-alpha (exploratory biomarker)
Time Frame: By day 84
|
Median changes in serum TNF-alpha
|
By day 84
|
Changes in CBC + differential (exploratory biomarker)
Time Frame: By day 84
|
Median variations in haemoglobin and leucocyte counts
|
By day 84
|
Level of anti-SARS-CoV2 antibodies (exploratory biomarker)
Time Frame: By day 84
|
Median titres od anti-SARS-CoV2 antibodies
|
By day 84
|
Virus eradication (exploratory biomarker)
Time Frame: By day 84
|
Proportion of patients with a positive swab for SARS-CoV2 by PCR
|
By day 84
|
Anti-drug antibodies (exploratory biomarker)
Time Frame: By day 84
|
Proportion of patients who developed anti-drug antibodies
|
By day 84
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lorenzo Dagna, MD, Ospedale San Raffaele
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- COVID-19
- Inflammation
- Respiratory Insufficiency
- Pneumonia
- Pneumonia, Viral
- Respiratory Distress Syndrome
- Antirheumatic Agents
- Mavrilimumab
Other Study ID Numbers
- COMBAT-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Mavrilimumab
-
MedImmune LLCMedImmune LtdCompletedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
-
MedImmune LLCMedImmune LtdCompletedA Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBulgaria, Poland, Russian Federation, Estonia, Hungary, Latvia, Lithuania, Romania, Ukraine, Czechia, Japan
-
MedImmune LLCTerminatedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico
-
MedImmune LLCCompletedHealthy VolunteersUnited Kingdom
-
Kiniksa Pharmaceuticals, Ltd.CompletedCOVIDUnited States, Brazil, South Africa, Chile, Peru
-
Virginia Commonwealth UniversityKiniksa Pharmaceuticals, Ltd.CompletedCOVID-19 | Pneumonia | Sars-CoV2United States
-
The Cleveland ClinicKiniksa Pharmaceuticals, Ltd.CompletedPneumonia | SARS-CoV 2 | COVID 19United States
-
Kristin HudockKiniksa Pharmaceuticals, Ltd.UnknownPneumonia | SARS-CoV 2 | COVID 19United States
-
MedImmune LLCCompletedRheumatoid ArthritisRussian Federation, Spain, United Kingdom, Argentina, Hungary, Israel, Portugal, Slovakia, Greece, Serbia, Czech Republic, Colombia, France, Mexico
-
Kiniksa Pharmaceuticals, Ltd.CompletedGiant Cell ArteritisUnited States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain